Crescent Biopharma (CBIO) Preferred Shares (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Preferred Shares of $4.0 million for Q2 2026, little changed year-over-year from $4.0 million in Q2 2025, and little changed quarter-over-quarter from $4.0 million in Q1 2026.
Crescent Biopharma (CBIO) Preferred Shares (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Preferred Shares for 3 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Preferred Shares changed 0.0% year-over-year to $4.0 million; the TTM figure through Jun 2026 stood at $4.0 million (changed 0.0% YoY), while the FY2025 annual figure was $4.0 million, changed N/A from the prior year.
- Preferred Shares was little changed at $4.0 million in Q2 2026 per CBIO's latest filing, from $4.0 million in the prior quarter.
- Across five years, Preferred Shares topped out at $4.0 million in Q2 2025 and bottomed at $4.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | - |
| 10 | Crescent Biopharma | 1.08 Bn | 904.64 Mn | - | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | 4.00 Mn |
| Sep 30, 2025 | 4.00 Mn |
| Jun 30, 2025 | 4.00 Mn |
| Dec 31, 2013 | 30,726.00 |